AlphaCrest Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

AlphaCrest Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,902	Closed	-$344K	–	1420
2022 Q1	$344K	Buy	+2,902	New	+$362K	0.02%	1061
2021 Q3	–	Sell	-3,104	Closed	-$301K	–	1441
2021 Q2	$301K	Buy	+3,104	New	+$252K	0.01%	1107
2021 Q1	–	Sell	-4,455	Closed	-$382K	–	1370
2020 Q4	$382K	Sell	4,455 -4,345	-49%	-$368K	0.03%	799
2020 Q3	$572K	Buy	8,800 +5,300	+151%	+$347K	0.06%	522
2020 Q2	$256K	Buy	+3,500	New	+$186K	0.04%	708

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AlphaCrest Capital Management's BHVN Position: Q2 2022 in Review

AlphaCrest Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 2,902 shares — an estimated $344K sold.

AlphaCrest Capital Management first reported a position in BHVN in Q2 2020 and held it in 5 quarters. The position peaked at $572K in Q3 2020. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

AlphaCrest Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 2,902 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $344K.
AlphaCrest Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2020 and held it in 5 quarters.
AlphaCrest Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $572K in Q3 2020.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on AlphaCrest Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.